Relationship of Clinical Symptoms with Biomarkers of Inflammation in Pediatric Inflammatory Bowel Disease

Overview

Journal Eur J Pediatr

Specialty Pediatrics

Date 2016 Aug 31

PMID 27573259

Citations 11

Authors

Daniel R Hoekman

Kay Diederen

Bart G P Koot

Merit M Tabbers

Angelika Kindermann

Marc A Benninga

Affiliations

Soon will be listed here.

Abstract

Unlabelled: In adult inflammatory bowel disease (IBD) patients, there is a strong discrepancy between symptoms and biomarkers of inflammation. Data on pediatric IBD patients are conflicting. Therefore, we aimed to investigate the relationship between clinical symptoms and biomarkers of inflammation in pediatric IBD. Patients aged <18 years with previously diagnosed Crohn's disease (CD) or ulcerative colitis (UC) were included. Clinical disease activity was determined using the abbreviated Pediatric CD Activity Index (aPCDAI) or Pediatric UC Activity Index (PUCAI). Biochemical disease activity was assessed using fecal calprotectin (FC) and C-reactive protein (CRP). In total, 127 patients (62 male; median age 14.9 years) were included (82 CD, 45 UC). FC correlated weakly with total aPCDAI score (r s = 0.32; 95 % CI 0.12-0.51; p = 0.003) and total PUCAI score (r s = 0.36; 95 % CI 0.07-0.62; p = 0.015). Only aPCDAI components abdominal examination and perirectal disease and PUCAI component activity level had a significant correlation with levels of FC. CRP correlated weakly with total aPCDAI score (r s = 0.28; 95 % CI 0.05-0.46; p = 0.012) and aPCDAI components abdominal examination and activity level. No significant correlation was observed between CRP and total PUCAI score (r s = 0.01; 95 % CI -0.34-0.29; p = 0.961) or individual PUCAI components.

Conclusion: There is a strong discrepancy between clinical symptoms and biomarkers of inflammation in children with IBD.

What Is Known: • A substantial proportion of asymptomatic pediatric inflammatory bowel disease (IBD) patients have elevated biomarkers of inflammation. • There is a strong discrepancy between symptoms and biomarkers of inflammation in adults with IBD. What is New: • Clinical symptoms are only weakly associated with levels of fecal calprotectin and serum C-reactive protein in children and adolescents with previously diagnosed IBD. • Similarly to adult IBD patients, there is a strong discrepancy between clinical symptoms and biomarkers of inflammation in children with IBD.

Citing Articles

Assessing the correlation between fecal calprotectin, blood markers and disease activity in pediatric inflammatory bowel disease.

Plume J, De A, Mutalib M Ann Gastroenterol. 2024; 37(4):436-441.

PMID: 38974077 PMC: 11226738. DOI: 10.20524/aog.2024.0892.

Correlation Between Serum and Fecal Biomarkers and Patient-Reported Outcomes in Patients with Crohn's Disease and Ulcerative Colitis.

Motwani K, Alizadeh M, Abutaleb A, Grossman J, Wellington J, Cross R Dig Dis Sci. 2024; 69(6):2154-2163.

PMID: 38580888 DOI: 10.1007/s10620-024-08421-w.

Dietary Therapy to Improve Nutrition and Gut Health in Paediatric Crohn's Disease; A Feasibility Study.

Allen S, Belnour S, Renji E, Carter B, Bray L, Allen A Nutrients. 2022; 14(21).

PMID: 36364868 PMC: 9655551. DOI: 10.3390/nu14214598.

Evaluation of Fecal Calprotectin, Serum C-Reactive Protein, Erythrocyte Sedimentation Rate, Seromucoid and Procalcitonin in the Diagnostics and Monitoring of Crohn's Disease in Children.

Akutko K, Iwanczak B J Clin Med. 2022; 11(20).

PMID: 36294408 PMC: 9604851. DOI: 10.3390/jcm11206086.

MRI-Based Radiomic Signature Identifying Secondary Loss of Response to Infliximab in Crohn's Disease.

Feng J, Feng Q, Chen Y, Yang T, Cheng S, Qiao Y Front Nutr. 2022; 8:773040.

PMID: 35047543 PMC: 8763017. DOI: 10.3389/fnut.2021.773040.

References

Ozgenc F, Ecevit C, Yagci R . C-reactive protein in children with active ulcerative colitis. J Pediatr. 2011; 160(3):530. DOI: 10.1016/j.jpeds.2011.11.047. View

Mooiweer E, Severs M, Schipper M, Fidder H, Siersema P, Laheij R . Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission. J Crohns Colitis. 2014; 9(1):50-5. DOI: 10.1093/ecco-jcc/jju003. View

Modigliani R, Mary J, Simon J, Cortot A, Soule J, Gendre J . Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives. Gastroenterology. 1990; 98(4):811-8. DOI: 10.1016/0016-5085(90)90002-i. View

Komraus M, Wos H, Wiecek S, Kajor M, Grzybowska-Chlebowczyk U . Usefulness of faecal calprotectin measurement in children with various types of inflammatory bowel disease. Mediators Inflamm. 2012; 2012:608249. PMC: 3361316. DOI: 10.1155/2012/608249. View

Bremner A, Roked S, Robinson R, Phillips I, Beattie M . Faecal calprotectin in children with chronic gastrointestinal symptoms. Acta Paediatr. 2006; 94(12):1855-8. DOI: 10.1111/j.1651-2227.2005.tb01870.x. View

Vermeire S, Van Assche G, Rutgeerts P . Laboratory markers in IBD: useful, magic, or unnecessary toys?. Gut. 2006; 55(3):426-31. PMC: 1856093. DOI: 10.1136/gut.2005.069476. View

Krzesiek E . Fecal Calprotectin as an Activity Marker of Inflammatory Bowel Disease in Children. Adv Clin Exp Med. 2016; 24(5):815-22. DOI: 10.17219/acem/26003. View

Wiernicka A, Szymanska S, Cielecka-Kuszyk J, Dadalski M, Kierkus J . Histological healing after infliximab induction therapy in children with ulcerative colitis. World J Gastroenterol. 2015; 21(37):10654-61. PMC: 4588087. DOI: 10.3748/wjg.v21.i37.10654. View

Rogler G, Biedermann L . Clinical Utility of Biomarkers in IBD. Curr Gastroenterol Rep. 2015; 17(7):26. DOI: 10.1007/s11894-015-0449-x. View

10.

Yoo S, Jung Y, Park J, Kim H, Cho Y, Sohn C . Fatigue severity and factors associated with high fatigue levels in Korean patients with inflammatory bowel disease. Gut Liver. 2014; 8(2):148-53. PMC: 3964264. DOI: 10.5009/gnl.2014.8.2.148. View

11.

Gerasimidis K, Nikolaou C, Edwards C, McGrogan P . Serial fecal calprotectin changes in children with Crohn's disease on treatment with exclusive enteral nutrition: associations with disease activity, treatment response, and prediction of a clinical relapse. J Clin Gastroenterol. 2010; 45(3):234-9. DOI: 10.1097/MCG.0b013e3181f39af5. View

12.

Sipponen T, Savilahti E, Kolho K, Nuutinen H, Turunen U, Farkkila M . Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis. 2007; 14(1):40-6. DOI: 10.1002/ibd.20312. View

13.

Shaoul R, Sladek M, Turner D, Paeregaard A, Veres G, Veereman Wauters G . Limitations of fecal calprotectin at diagnosis in untreated pediatric Crohn's disease. Inflamm Bowel Dis. 2012; 18(8):1493-7. DOI: 10.1002/ibd.21875. View

14.

Voiosu T, Bengus A, Dinu R, Voiosu A, Balanescu P, Baicus C . Rapid fecal calprotectin level assessment and the SIBDQ score can accurately detect active mucosal inflammation in IBD patients in clinical remission: a prospective study. J Gastrointestin Liver Dis. 2014; 23(3):273-8. DOI: 10.15403/jgld.2014.1121.233.thv. View

15.

Scaioli E, Scagliarini M, Cardamone C, Liverani E, Ugolini G, Festi D . Clinical application of faecal calprotectin in ulcerative colitis patients. Eur J Gastroenterol Hepatol. 2015; 27(12):1418-24. DOI: 10.1097/MEG.0000000000000461. View

16.

Schoepfer A, Beglinger C, Straumann A, Trummler M, Vavricka S, Bruegger L . Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2009; 105(1):162-9. DOI: 10.1038/ajg.2009.545. View

17.

Osterman M, Aberra F, Cross R, Liakos S, McCabe R, Shafran I . Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol. 2014; 12(11):1887-93.e3. PMC: 4214893. DOI: 10.1016/j.cgh.2014.03.035. View

18.

Mosli M, Zou G, Garg S, Feagan S, MacDonald J, Chande N . C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2015; 110(6):802-19. DOI: 10.1038/ajg.2015.120. View

19.

Sipponen T, Kolho K . Faecal calprotectin in children with clinically quiescent inflammatory bowel disease. Scand J Gastroenterol. 2010; 45(7-8):872-7. DOI: 10.3109/00365521003782389. View

20.

Shepanski M, Markowitz J, Mamula P, Hurd L, Baldassano R . Is an abbreviated Pediatric Crohn's Disease Activity Index better than the original?. J Pediatr Gastroenterol Nutr. 2004; 39(1):68-72. DOI: 10.1097/00005176-200407000-00014. View